Novel histone deacetylase inhibitors, process for preparation and uses thereof

A compound of the formula (I):

• wherein,
• A is selected from the group consisting of:
• H, —NO2, —NH2, alkyl, alkenyl, haloalkyl, haloalkenyl, heteroalkyl, alkoxy, alkoxyalkyl, alkenyloxy, alkynyloxy, alkylamino, aminoalkyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, aminosulfonyl, acyl, arylalkyl, cycloalkylaryl, heteroaryl, and heterocycloalkyl, each of which is optionally substituted by one or more substituent selected from the group consisting of halogen, ═O, —CF3, alkyl, alkenyl, alkynyl, hydroxyl, hydroxyalkyl, alkoxy, alkoxyalkyl;
• X is a covalent bond or a residual selected from the group consisting of methylene, —O—, —S—, —NH—, —NR7—, —CO—NH—, —CO—NR7—, —NH—CO—, —NR7—CO—, —SO2NH—, —NH—SO2—, —NH—CO—NH—, —NH—CS—NH—, —CO—NH—CO—NH— and —CS—NH—CO—NH—;
• when X is —NH— or —NR7—, A is neither aryl, heterocycloaryl, cycloalkenyl nor Heterocycloalkeny;
• Y is selected from the group consisting of —O—, —S—, —NH— and —S(O)—;
• X and Y are respectively attached to the phenyl ring position C3, C4 and or C5;
• Q is selected from a group consisting of —(CR8R9)n-, —(CR8R9)n-X—(CR10R11)m-, —Ar—X—(CR10R11)m-, —(CR8R9)n-X—Ar—, -Cy-X—(CR10R11)m- and —(CR8R9)n-X-Cy-;
• n and m are independently 1, 2, 3, 4, 5 or 6;
• Z is a C2-C6 alkenyl;
• R1 and R2 are same or different and are selected independently from a group consisting of H, alkyl, alkenyl, haloalkyl, haloalkynyl, heteroalkyl, alkoxy, alkoxyalkyl, alkenoxy, alkynyloxy, amino, alkylamino, aminoalkyl, alkoxylcarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, aminosulfonyl and acyl, each of which is optionally substituted by one or more substituent selected from the group consisting of halogen, ═O, ═S, —CF3, —OCF3, alkyl, alkenyl, alkynyl, hydroxyl, hydroxyalkyl, alkoxy, alkoxyalkyl;
• alkenoxy, alkynyloxy, amino, alkylamino;
• R3 is selected from the group consisting of H, nitro, amino, alkyl and halogen;
• R7 is H, alkyl alkenyl, haloalkyl, haloalkenyl, cycloalkyl, heteroalkyl, hydroxyl, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenoxy, alkynoxy, cycloalkoxy, heterocycloalkoxy, amino, alkylamino, aminoalkyl, amide, COOH, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, aminosulfonyl, or acyl;
• each of which is optionally substituted by one or more substituent selected from halogen, ═O, ═S, —CN, —NO2, —CF3, —OCF3, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyl, hydroxyalkyl, alkoxy, alkoxyalkyl, alkenoxy, alkynoxy, amino, alkylamino, sulfonyl, alkylsulfonyl, aminosulfonyl, —COOH, —C(O)OR4, —COR5, —SH, —SR6, —OR6 and acyl;
• R5, R6, R8, R9, R10 and R11 are independently from each other selected from a group consisting of H, alkyl, alkenyl, haloalkyl, haloalkenyl, cycloalkyl, heteroalkyl, hydroxyl, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenoxy, alkynoxy, cycloalkoxy, heterocycloalkoxy, amino, alkylamino, aminoalkyl, amide, COOH, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, aminosulfonyl and acyl;
• Ar is aryl or heteroaryl, each of which is optionally substituted by one or more substituent selected from halogen, —CF3, alkyl, alkenyl, alkynyl, hydroxy, hydroxyalkyl, alkoxy or alkoxyalkyl;
• Cy is cycloalkyl or heterocycloalkyl, each of which is optionally substituted by one or more substituent selected from halogen, ═O, —CF3, alkyl, alkenyl, alkynyl, hydroxy, hydroxyalkyl, alkoxy or alkoxyalkyl;
• or pharmaceutically acceptable salts, or prodrug thereof.